Alzheimer’s disease (AD) is one of the most prominent and feared neurodegenerative diseases associated with aging. A hallmark of this disease is the formation of extra-cellular amyloid plaques in the brain. The principle component of these extracellular plaques is amyloid-ß protein (Aß). Though the mechanisms underlying Alzheimer’s disease pathology remain controversial, accumulation and deposition of Aß appears to play a critical role in the pathogenesis of AD.
Amyloid-ß protein is formed through cleavage of amyloid precursor protein (APP) by beta-secretase. Alternatively, cleavage of APP by alpha-secretase, results in a non-pathogenic outcome and no accumulation of Aß. A viable therapeutic approach therefore might be to facilitate the clearance and reduction of Aß by targeting these pathways.
Researchers at Arizona State University have successfully synthesized a bi-functional recombinant antibody as a treatment for AD. The bi-specific construct is composed of two single chain antibody fragments (scFV): one that blocks beta-secretase activity by binding to the substrate APP (but not Aß), and a second that promotes alpha-secretase activity by specifically cleaving at the alpha-secretase site of Aß or APP.
This invention may have significant potential as an effective therapeutic for AD.
- Antibody to treat Alzheimer’s Disease
Benefits and Advantages
- Non-inflammatory: Antibody fragment is derived from a humanized library
- Specific: The antibody fragment binds to amyloid precursor protein without cross-reacting with amyloid-ß protein
- Bifunctional: The antibody fragment blocks formation of Aß and promotes non-pathogenic (alpha-secretase mediated) cleavage of amyloid precursor protein
For more information about the inventor(s) and their research, please see
Dr. Sierks' directory webpage
Dr. Sierks' laboratory webpage